Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10363224	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (9 years from now)
US8889190	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (9 years from now)
US9101545	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (9 years from now)
US9555005	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (9 years from now)
US8652527	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (9 years from now)

Qudexy Xr is owned by Upsher Smith Labs.

Qudexy Xr contains Topiramate.

Qudexy Xr has a total of 5 drug patents out of which 0 drug patents have expired.

Qudexy Xr was authorised for market use on 11 March, 2014.

Qudexy Xr is available in capsule, extended release;oral dosage forms.

Qudexy Xr can be used as treatment of seizures.

The generics of Qudexy Xr are possible to be released after 19 March, 2033.

Market Authorisation Date: 11 March, 2014

Treatment: Treatment of seizures

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
25 mg, 50 mg, 100 mg, 150 mg, and 200 mg	24 Dec, 2015	1		19 Mar, 2033	Extinguished Non-Forfeiture

Strength	Dosage	Availability
25MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
50MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
100MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
150MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
200MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

QUDEXY XR family patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic